Andrew Brown
About Andrew Brown
Andrew Brown is an Associate Scientist at Precision NanoSystems Inc., specializing in lipid nanoparticle drug delivery systems. He is pursuing a PhD to advance his research in gene and cell-based therapeutics.
Current Role at Precision NanoSystems
Andrew Brown currently serves as an Associate Scientist at Precision NanoSystems Inc. in Vancouver, British Columbia, Canada. He has held this position since 2020, contributing to the company's research and development efforts in the field of gene and cell-based therapeutics. His work focuses on advancing the design and manufacturing processes of lipid nanoparticle drug delivery systems.
Previous Experience at Precision NanoSystems
Before his current role, Andrew Brown worked at Precision NanoSystems Inc. in various capacities. He served as a Research Associate for 11 months in 2019 and as a Formulations & Drug Delivery Technician from 2017 to 2018 for one year. Additionally, he was a Formulations Intern for 7 months in 2016. His experiences at the company have contributed to his expertise in drug delivery systems.
Work History at Environment Canada
Andrew Brown worked at Environment Canada as a Reference Materials Technologist for 7 months in 2015 in Burlington, Ontario. In this role, he focused on the development and management of reference materials, contributing to environmental monitoring and assessment initiatives.
Educational Background in Chemistry
Andrew Brown studied at McMaster University, where he pursued a Bachelor of Science (B.S.) degree in Chemistry with a co-op program from 2012 to 2017. His education provided a strong foundation in chemical principles, which he applies in his current research on drug delivery systems and therapeutics.
Focus on Gene and Cell-Based Therapeutics
Andrew Brown is currently pursuing graduate studies with the aim of obtaining a PhD. His research interests are centered on gene and cell-based therapeutics, with a particular emphasis on non-viral vector design. He aims to enhance the development and manufacturing processes of advanced therapies in this field.